SG11201905259SA - Preferred pairing of antibody domains - Google Patents
Preferred pairing of antibody domainsInfo
- Publication number
- SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibody
- domain
- domains
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154388 | 2017-02-02 | ||
| PCT/EP2018/052624 WO2018141894A1 (fr) | 2017-02-02 | 2018-02-02 | Appariement préféré de domaines d'anticorps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201905259SA true SG11201905259SA (en) | 2019-08-27 |
Family
ID=57965749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201905259SA SG11201905259SA (en) | 2017-02-02 | 2018-02-02 | Preferred pairing of antibody domains |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190352429A1 (fr) |
| EP (1) | EP3577137A1 (fr) |
| JP (1) | JP7123063B2 (fr) |
| KR (1) | KR20190113870A (fr) |
| CN (1) | CN110382537B (fr) |
| AU (1) | AU2018214208A1 (fr) |
| BR (1) | BR112019013648A2 (fr) |
| CA (1) | CA3050988A1 (fr) |
| IL (1) | IL268401A (fr) |
| MX (1) | MX2019007984A (fr) |
| SG (1) | SG11201905259SA (fr) |
| WO (1) | WO2018141894A1 (fr) |
| ZA (1) | ZA201903796B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6932693B2 (ja) | 2015-10-08 | 2021-09-08 | ザイムワークス，インコーポレイテッド | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU777192B2 (en) * | 1994-05-27 | 2004-10-07 | Ariad Gene Therapeutics, Inc. | Immunosuppressant target proteins |
| JP4836451B2 (ja) * | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
| CN101022828B (zh) * | 2004-02-10 | 2014-12-10 | 科罗拉多大学评议会 | B因子、补体旁路的抑制及与此相关的方法 |
| PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
| PL2167128T3 (pl) | 2007-07-17 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v |
| CN101348475B (zh) * | 2007-07-20 | 2011-03-30 | 重庆人本药物研究院 | 一种奥利司他合成方法、中间体化合物及其制备方法 |
| KR101431319B1 (ko) | 2009-05-27 | 2014-08-20 | 에프. 호프만-라 로슈 아게 | 삼중특이성 또는 사중특이성 항체 |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| KR102052774B1 (ko) * | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| WO2014001324A1 (fr) * | 2012-06-27 | 2014-01-03 | Hoffmann-La Roche Ag | Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP2970435B1 (fr) | 2013-03-15 | 2020-08-12 | Eli Lilly and Company | Procédés de production de fab et d'anticorps bispécifiques |
| US10982008B2 (en) * | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
-
2018
- 2018-02-02 CN CN201880009856.1A patent/CN110382537B/zh active Active
- 2018-02-02 EP EP18704923.4A patent/EP3577137A1/fr active Pending
- 2018-02-02 MX MX2019007984A patent/MX2019007984A/es unknown
- 2018-02-02 BR BR112019013648A patent/BR112019013648A2/pt unknown
- 2018-02-02 US US16/476,380 patent/US20190352429A1/en not_active Abandoned
- 2018-02-02 KR KR1020197025298A patent/KR20190113870A/ko not_active Application Discontinuation
- 2018-02-02 WO PCT/EP2018/052624 patent/WO2018141894A1/fr unknown
- 2018-02-02 AU AU2018214208A patent/AU2018214208A1/en active Pending
- 2018-02-02 CA CA3050988A patent/CA3050988A1/fr active Pending
- 2018-02-02 SG SG11201905259SA patent/SG11201905259SA/en unknown
- 2018-02-02 JP JP2019541726A patent/JP7123063B2/ja active Active
-
2019
- 2019-06-12 ZA ZA2019/03796A patent/ZA201903796B/en unknown
- 2019-07-31 IL IL268401A patent/IL268401A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190113870A (ko) | 2019-10-08 |
| IL268401A (en) | 2019-09-26 |
| RU2019119391A (ru) | 2021-03-02 |
| BR112019013648A2 (pt) | 2020-01-21 |
| RU2019119391A3 (fr) | 2021-05-25 |
| US20190352429A1 (en) | 2019-11-21 |
| EP3577137A1 (fr) | 2019-12-11 |
| ZA201903796B (en) | 2022-11-30 |
| MX2019007984A (es) | 2019-10-15 |
| WO2018141894A1 (fr) | 2018-08-09 |
| JP7123063B2 (ja) | 2022-08-22 |
| CN110382537A (zh) | 2019-10-25 |
| CN110382537B (zh) | 2023-07-25 |
| CA3050988A1 (fr) | 2018-08-09 |
| AU2018214208A1 (en) | 2019-07-11 |
| JP2020505929A (ja) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408056YA (en) | Fire suppression systems, devices, and methods | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |